No Detail Found!

In Silico Identification of Garlic Phytochemicals as a Novel Anti- VEGFR2 Agent to Inhibit Cancer-Associated VEGFR2 Pathways Leading to Cancer

Author(s)
Noorah Alsowayeh Department of Biology, College of Science Al-Zulfi, Majmaah University, Al-Majmaah 11952, Saudi Arabia
Faiz Abdulaziz Alfaiz Department of Biology, College of Science Al-Zulfi, Majmaah University, Al-Majmaah 11952, Saudi Arabia
Abdulaziz S. Alothaim Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11952, Saudi Arabia
Enas S. Ahmed Department of Biology, College of Science Al-Zulfi, Majmaah University, Al-Majmaah 11952, Saudi Arabia
Azfar Jamal Department of Biology, College of Science Al-Zulfi, Majmaah University, Al-Majmaah 11952, Saudi Arabia
Abstract
Introduction: Vascular endothelial growth factor receptor 2 (VEGFR2) plays an important role in cancer progression, especially in tumor growth and metastasis. Although several FDA-approved drugs target VEGFR2, they are often associated with side effects. Therefore, there is a need to identify safer and effective alternative molecules. Methods: In this study, the VEGFR2 protein (PDB ID: 2OH4) was obtained from the Protein Data Bank and prepared for molecular docking. A total of 18 garlic-derived phytochemicals and a standard drug, famitinib, were retrieved from the PubChem database. Molecular docking was performed using AutoDock Vina in PyRx to evaluate binding affinity. Basic pharmacokinetic properties of selected compounds were also assessed. Results: Among the tested compounds, three molecules (CID: 5280343, 5280863 and 5280805) showed better binding affinity (-9.6, -9.4 and -9.1 kcal/mol, respectively) compared to famitinib (-8.3 kcal/mol). These compounds also formed stable interactions within the VEGFR2 active site and showed acceptable pharmacokinetic properties. Conclusion: The results suggest that garlic phytochemicals may act as potential inhibitors of VEGFR2. However, these findings are based on computational analysis and require further validation through experimental studies.
Publication Details
Page(s) 210-215
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: s1, Year: 2026

Request the full text from PASTIC

Keywords
Protein Data Bank (PDB ID, AutoDock Vina, Famitinib, PyRx, Cancer progression, 2OH4), VEGFR2
References
Ferrara N. . .The Biology of VEGF and Its Receptors. Nature Medicine, 9(2003) : 669-676.
Holmes K. .2007 .Vascular Endothelial Growth Factor Receptor-2: Structure. Intracellular Signalling and Therapeutic Inhibition.” Cellular Signalling, 19 : 2003-2012.
Shibuya M.,Pro-Angiogenic Therapies M. . .Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-. ” Genes and Cancer, 2(2011) : 1097-1105.
Shibuya M. .2013 .Vascular Endothelial Growth Factor and Its Receptor System: Physiological Functions in Angiogenesis and Pathological Roles in Various Diseases. ” Journal of Biochemistry, 153 : 13-19.
Olsson A.K. . .. VEGF Receptor Signalling-In Control of Vascular Function.” Nature Reviews Molecular Cell Biology, 7(2006) : 359-371.
Simons M. .2016 .Mechanisms and Regulation of Endothelial VEGF Receptor Signalling. Nature Reviews Molecular Cell Biology, 17 : 611-625.
McTigue M. . .Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis. ” Structure, 7(1999) : 319-330.
Liu X. . .ANGPTL2/LILRB2 Signaling Promotes the Propagation of Lung Cancer Cells. ” Oncotarget, 6(2015) : 21004-21015.
Rafii S.,Lyden D. .2008 .Cancer: A Few to Flip the Angiogenic Switch. Science, 319 : 163-164.
Matsumoto T. .2005 .VEGF Receptor-2 Y951 Signaling and a Role for the Adapter Molecule TSAd in Tumor Angiogenesis. EMBO Journal, 24 : 2342-2353.
Kowanetz M.,Ferrara N. .2006 .. Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective.” Clinical Cancer Research, 12 : 5018-5022.
Fuchs C.S. .2014 .Phase 3 Trial.” The Lancet. , 383 : 31-39.
Llovet J.M. .2008 .. Sorafenib in Advanced Hepatocellular Carcinoma.” New England Journal of Medicine, 359 : 378-390.
Leong A.,Kim M. .2020 .The Angiopoietin-2 and Tie Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. International Journal of Molecular Sciences, 21 : 1-20.
Moserle L.,Casanovas O. .2013 .Anti-Angiogenesis and Metastasis: A Tumour and Stromal Cell Alliance. ” Journal of Internal Medicine, 273 : 128-137.
Casanovas O. . .Drug Resistance by Evasion of Antiangiogenic Targeting of VEGF Signaling in Late-Stage Pancreatic Islet Tumors. ” Cancer Cell, 8(2005) : 299-309.
López-Lázaro M.,Current Medicinal Chemistry-Anti-Cancer Agents . .Flavonoids as Anticancer Agents: Structure-Activity Relationship Study. , 2(2002) : 691-714.
Bisht S. .2007 .Polymeric Nanoparticle-Encapsulated Curcumin ('Nanocurcumin'): A Novel Strategy for Human Cancer Therapy. ” Journal of Nanobiotechnology, 5 : .
Madadi N.R. .2015 .Synthesis and Evaluation of a Series of Resveratrol Analogues as Potent Anti-Cancer Agents That Target Tubulin. MedChemComm, 6 : .
Patel N. .2025 .Investigating the Role of Natural Flavonoids in VEGFR Inhibition: Molecular Modelling and Biological Activity in A549 Lung Cancer Cells. ” Journal of Molecular Structure, 1322 : 140392.
Zhang Y. .2020 .Phytochemicals of Garlic: Promising Candidates for Cancer Therapy. ” Biomedicine and Pharmacotherapy, 123 : 109730.
Talib W.H. .2024 .. Allicin and Cancer Hallmarks.” Molecules, 29 : .
Xiao D. .2006 .Diallyl Trisulfide Inhibits Angiogenic Features of Human Umbilical Vein Endothelial Cells by Causing Akt Inactivation and Down-Regulation of VEGF and VEGF-R2.” Nutrition and Cancer. , 55 : 94-107.
0

Citations

0

Downloads

18

Views